bioAffinity Technologies Inc. (BIAF) — RQD Stock Rating Cockpit

The per the Roarable RQD rating, BIAF receives an RQD Score of 29 and a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 8 / 20 (ROIC -35%; FCF yield 0%), signaling that the business is not currently generating economic returns or free cash flow. Whale/13F Flow scores 3 / 20 and Insider Conviction scores 3 / 20, indicating weak institutional and insider-side support in the sourced positioning data. Macro Regime Fit scores 7 / 20 with a Beta of 1.0, meaning the rating sees limited macro-regime alignment. Forensic Balance Sheet scores 8 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), reflecting a weak accounting-quality profile.

For a prospective investor evaluating the stock today, the implication is that the rating framework views the equity primarily as a high-risk, low-quality position. Upside drivers would have to come from outside the reported cash engine, since current economics show negative operating margin (-60%) and negative net margin (-60%). Valuation tradeoffs are difficult to assess because P/E, EPS, and EV/EBITDA are not available in source data, and the market cap of $3.9M sits against a 52-week range of $2.66 - $80.7, a span that underscores extreme price volatility. Any constructive case would need to rest on catalysts rather than on current cash generation.

bioAffinity Technologies Inc. (BIAF) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Commercial Physical & Biological Resarch industry. The source data identifies the company's sector, industry, and exchange, but does not describe its specific products, customers, or revenue model. Revenue is reported in the financial data (FY 2025: $6.2M; FY 2024: $9.4M; FY 2023: $2.5M), which indicates the company generates sales, though the sources do not detail how those sales are generated. Recent news headlines reference a lung cancer risk test (a home-collected test) and a product referred to as CyPath Lung, which suggest diagnostic activity, but the source data does not confirm the full product or go-to-market structure.

Per the SEC financials, reported revenue rose to $6.2M in FY 2025 from $9.4M in FY 2024 after being $2.5M in FY 2023, while net losses persisted in each period. Gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -35% per the market data. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. The balance sheet shows FY 2025 cash of $6.4M against FCF of $-9.4M, and debt is not available in source data for any period.

• Financing (YELLOW, Market Wire): A Business Wire report describes an approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement priced At-The-Market under Nasdaq Rules, and a separate report covers the closing of that financing via WallachBeth Capital. Financing activity of this kind is relevant against the negative free cash flow shown in the financials.
• Regulatory (RED, Risk Watch): A Stock Titan report states that Japan intends to grant a patent for a home-collected lung cancer risk test, labeled as a risk-watch item in the feed.
• Price action (RED, Risk Watch): A Timothy Sykes report headlined "BIAF Stock Slides As Traders Weigh Heavy Losses And Volatility" is flagged as a risk-watch item.
• Product momentum (GREEN, Catalyst): A StocksToTrade report references CyPath Lung growth as a catalyst.
• Proprietary liquidity signal (BULLISH): The Butterfly Supply-Chain Graph assigns a LIQUIDITY_TAILWIND signal with severity 94 and a Macro Tailwind Score of 96/100, citing a 6.00x True Net Liquidity Elasticity (r = -0.35) and a True Net Liquidity Index of $5,745.73B (-0.64% 4-week RoC; High-Yield OAS +2 bps). This signal is macro-driven and is not a company-specific fundamental.

The Butterfly Supply-Chain Graph lists supply_chain as NONE and contains no butterfly links, so upstream suppliers, downstream customers, and cross-company dependencies are not available in source data. The only sector context provided is Health Care / Biotechnology: Commercial Physical & Biological Resarch. The proprietary liquidity signal implies that BIAF's price sensitivity to net liquidity conditions is high (6.00x elasticity per the graph), meaning second-order moves in Fed balance-sheet and Treasury liquidity could amplify price swings in either direction. Investors should watch the financing cadence: a registered direct offering at market price, combined with negative free cash flow, creates a dilution pathway whose magnitude is not quantified in the source data.

• What specific products and revenue streams generate the $6.2M FY 2025 revenue, and how much is recurring versus one-time?
• What is the outstanding debt balance, since debt is listed as N/A across all reported periods?
• What were the share count and dilution effects from the approximately $4 Million financing, and at what price per share were shares issued?
• What is the cash runway implied by FY 2025 cash of $6.4M against FCF of $-9.4M?
• What is the status and commercial impact of the Japan patent grant and the CyPath Lung product, and do these translate into reported revenue?